• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗β2糖蛋白1结构域抗体作为抗磷脂综合征的诊断标志物和血栓形成的预测指标:一项系统评价和荟萃分析

Anti-β2 glycoprotein domain 1 antibody as a diagnostic marker for antiphospholipid syndrome and a predictor of thrombosis: a systematic review and meta-analysis.

作者信息

Li Linhui, Chen Jian, Feng Jing, Zhao Hong, Liu Xiaojuan, Jiang Yongmei

机构信息

Department of Laboratory Medicine, West China Second University Hospital, Sichuan University, Chengdu, China.

Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, China.

出版信息

Front Immunol. 2025 Apr 23;16:1541165. doi: 10.3389/fimmu.2025.1541165. eCollection 2025.

DOI:10.3389/fimmu.2025.1541165
PMID:40336949
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12056313/
Abstract

Anti-β2 glycoprotein I domain 1 (anti-β2GPI-D1) antibodies have shown promise as diagnostic and prognostic markers for antiphospholipid syndrome (APS), but their clinical significance remains uncertain. This systematic review and meta-analysis evaluated the diagnostic accuracy of anti-β2GPI-D1 for APS and its association with thrombotic risk. A comprehensive search was conducted across PubMed, Web of Science, and Embase up to July 18, 2024. Eighteen studies (2,060 APS patients and 3,013 controls) were included in the diagnostic analysis, revealing a pooled sensitivity of 52% (95% CI 46%-58%) and specificity of 95% (95% CI 88%-98%). Anti-β2GPI-D1 demonstrated strong diagnostic value in distinguishing APS from other autoimmune diseases and healthy individuals, though its utility in differentiating APS from aPL carriers was limited. Additionally, five prospective cohort studies (210 APS patients, 430 aPL carriers, and 42 SLE patients) showed that anti-β2GPI-D1 was associated with an increased risk of thrombosis (pooled RR 1.75, 95% CI 1.07-2.87). Our findings suggest that anti-β2GPI-D1 offers high specificity and moderate sensitivity for APS diagnosis and may serve as a predictor of thrombosis.

摘要

抗β2糖蛋白I结构域1(抗β2GPI-D1)抗体已显示出作为抗磷脂综合征(APS)诊断和预后标志物的潜力,但其临床意义仍不明确。本系统评价和荟萃分析评估了抗β2GPI-D1对APS的诊断准确性及其与血栓形成风险的关联。截至2024年7月18日,在PubMed、科学网和Embase上进行了全面检索。诊断分析纳入了18项研究(2060例APS患者和3013例对照),汇总敏感性为52%(95%CI 46%-58%),特异性为95%(95%CI 88%-98%)。抗β2GPI-D1在区分APS与其他自身免疫性疾病和健康个体方面具有较强的诊断价值,但其在区分APS与抗磷脂抗体(aPL)携带者方面的效用有限。此外,五项前瞻性队列研究(210例APS患者、430例aPL携带者和42例系统性红斑狼疮患者)表明,抗β2GPI-D1与血栓形成风险增加相关(汇总RR 1.75,95%CI 1.07-2.87)。我们的研究结果表明,抗β2GPI-D1对APS诊断具有高特异性和中等敏感性,可能作为血栓形成的预测指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e036/12056313/1810ce566b2c/fimmu-16-1541165-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e036/12056313/1810ce566b2c/fimmu-16-1541165-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e036/12056313/1810ce566b2c/fimmu-16-1541165-g001.jpg

相似文献

1
Anti-β2 glycoprotein domain 1 antibody as a diagnostic marker for antiphospholipid syndrome and a predictor of thrombosis: a systematic review and meta-analysis.抗β2糖蛋白1结构域抗体作为抗磷脂综合征的诊断标志物和血栓形成的预测指标:一项系统评价和荟萃分析
Front Immunol. 2025 Apr 23;16:1541165. doi: 10.3389/fimmu.2025.1541165. eCollection 2025.
2
Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome.抗β2-糖蛋白 I 抗体抗域 1 在抗磷脂综合征中的临床意义。
Thromb Res. 2017 May;153:90-94. doi: 10.1016/j.thromres.2017.02.019. Epub 2017 Feb 24.
3
Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome.抗域 1-β2 糖蛋白 I 抗体在抗磷脂综合征的诊断和危险分层中的作用。
J Thromb Haemost. 2016 Sep;14(9):1779-87. doi: 10.1111/jth.13389. Epub 2016 Aug 24.
4
Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome.通过检测 IgG 抗体针对β2-糖蛋白 I 结构域 1 和结构域 4/5 对抗磷脂综合征进行临床特征分析:抗结构域 1 与抗结构域 4/5 的比值作为抗磷脂综合征的一种有用的新型生物标志物。
Arthritis Rheumatol. 2015 May;67(8):2196-204. doi: 10.1002/art.39187.
5
Beyond thrombosis: Anti-β2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome.抗β2糖蛋白 I 结构域 1 抗体与抗磷脂综合征的晚期妊娠不良结局相关,而非血栓栓塞事件。
J Autoimmun. 2018 Jun;90:76-83. doi: 10.1016/j.jaut.2018.02.002. Epub 2018 Feb 14.
6
Anti-β2GPI domain 1 antibodies stratify high risk of thrombosis and late pregnancy morbidity in a large cohort of Chinese patients with antiphospholipid syndrome.抗β2糖蛋白 I 结构域 1 抗体在一大群中国抗磷脂综合征患者中分层高血栓风险和晚期妊娠发病率。
Thromb Res. 2020 Jan;185:142-149. doi: 10.1016/j.thromres.2019.11.029. Epub 2019 Nov 28.
7
Both IgG and IgM anti-beta2 glycoprotein I antibodies assays are clinically useful to the antiphospholipid syndrome diagnosis.IgG和IgM抗β2糖蛋白I抗体检测在抗磷脂综合征诊断中均具有临床应用价值。
Acta Clin Belg. 2014 Dec;69(6):433-8. doi: 10.1179/2295333714Y.0000000060. Epub 2014 Aug 7.
8
Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome.采用化学发光免疫分析法检测原发性抗磷脂综合征中IgG抗结构域Iβ2糖蛋白I抗体
Clin Chim Acta. 2015 Jun 15;446:201-5. doi: 10.1016/j.cca.2015.04.033. Epub 2015 Apr 30.
9
Clinical significance and correlations between anti-β2 glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus.抗磷脂综合征和/或系统性红斑狼疮中抗β2 糖蛋白 I IgA 检测的临床意义及相关性。
Clin Chim Acta. 2016 Sep 1;460:107-13. doi: 10.1016/j.cca.2016.06.025. Epub 2016 Jun 23.
10
Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome.孤立性IgA抗β2糖蛋白I阳性在抗磷脂综合征诊断中的价值。
Arthritis Rheum. 2013 Dec;65(12):3186-93. doi: 10.1002/art.38131.

本文引用的文献

1
Viewpoint: The value of non-criteria antiphospholipid antibodies.观点:非标准抗磷脂抗体的价值。
Rheumatology (Oxford). 2024 Feb 6;63(SI):SI64-SI71. doi: 10.1093/rheumatology/kead632.
2
Antibodies to Domain I β-Glycoprotein 1 in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus.抗磷脂抗体综合征与系统性红斑狼疮患者中抗 I 型 β 糖蛋白 1 抗体。
Dokl Biochem Biophys. 2023 Aug;511(1):219-226. doi: 10.1134/S1607672923700278. Epub 2023 Oct 13.
3
2023 ACR/EULAR antiphospholipid syndrome classification criteria.
2023 年 ACR/EULAR 抗磷脂综合征分类标准。
Ann Rheum Dis. 2023 Oct;82(10):1258-1270. doi: 10.1136/ard-2023-224609. Epub 2023 Aug 28.
4
The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.2023年美国风湿病学会/欧洲抗风湿病联盟抗磷脂综合征分类标准。
Arthritis Rheumatol. 2023 Oct;75(10):1687-1702. doi: 10.1002/art.42624. Epub 2023 Aug 28.
5
Anti-β2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China.抗β2糖蛋白 I 结构域 I 抗体与中国大型前瞻性抗磷脂综合征队列中的超标准表现相关。
Lupus Sci Med. 2023 Aug;10(2). doi: 10.1136/lupus-2023-000924.
6
Profile and clinical relevance of non-criteria antiphospholipid antibodies in patients diagnosed with or highly suspected of APS.诊断或高度怀疑抗磷脂综合征(APS)患者的非标准抗磷脂抗体的特征和临床相关性。
Rheumatology (Oxford). 2024 Mar 1;63(3):891-900. doi: 10.1093/rheumatology/kead303.
7
Fluctuation of Anti-Domain 1 and Anti-β -Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies.抗磷脂抗体持续阳性患者体内抗域 1 和抗 β-糖蛋白 I 抗体效价随时间的波动。
Arthritis Rheumatol. 2023 Jun;75(6):984-995. doi: 10.1002/art.42459. Epub 2023 Apr 2.
8
A systematic review of the association between anti-β-2 glycoprotein I antibodies and APS manifestations.抗β2糖蛋白 I 抗体与 APS 表现相关的系统评价。
Blood Adv. 2021 Oct 26;5(20):3931-3936. doi: 10.1182/bloodadvances.2021005205.
9
Double positivity of anti-β-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies enhances both thrombosis and positivity of anti-ADAMTS13 antibody.抗β-糖蛋白I结构域I抗体和抗磷脂酰丝氨酸/凝血酶原抗体的双重阳性增强了血栓形成以及抗ADAMTS13抗体的阳性率。
J Thromb Thrombolysis. 2021 Nov;52(4):1133-1136. doi: 10.1007/s11239-021-02406-6. Epub 2021 Apr 29.
10
Improving the clinical accuracy in patients with antiphospholipid antibodies using anti-phosphatidylserine/prothrombin and anti-beta2 glycoprotein I domain and particle-based multi-analyte technology.使用抗磷脂酰丝氨酸/凝血酶原和抗β2糖蛋白I结构域及基于颗粒的多分析物技术提高抗磷脂抗体患者的临床诊断准确性。
Thromb Res. 2021 Jun;202:100-103. doi: 10.1016/j.thromres.2021.03.019. Epub 2021 Mar 22.